Mesa Laboratories (NASDAQ:MLAB) Releases Earnings Results, Misses Expectations By $1.54 EPS

Key Points

• Mesa Laboratories reported quarterly EPS of $0.75, missing analyst expectations of $2.29 by $1.54, while revenue of $62.34 million slightly exceeded estimates.
• Organic revenue growth accelerated to 2.6% in Q2, but Biopharmaceutical Development fell 8.2% amid export-control and shipment delays. Management forecast fiscal 2027 revenue of $250 million–$255 million and adjusted EBITDA of $66 million–$68 million.
• Sterilization and Disinfection Control grew 14.6%, though a key product line still faces delivery-reliability problems. Mesa is restructuring Clinical Genomics and expects about $5 million in net annualized cost reductions.

Mesa Laboratories (NASDAQ:MLAB - Get Free Report) released its quarterly earnings data on Monday. The medical instruments supplier reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.29 by ($1.54), FiscalAI reports. Mesa Laboratories had a return on equity of 22.72% and a net margin of 1.92%. The firm had revenue of $62.34 million for the quarter, compared to analyst estimates of $62.20 million.

Here are the key takeaways from Mesa Laboratories' conference call:

• Organic revenue growth accelerated to 2.6% in Q2 from 1% in Q1, and was about 5% excluding Clinical Genomics. Sterilization and Disinfection Control grew in the mid-teens and Calibration Solutions about 3.5%, while Biopharmaceutical Development declined 8.2% due to export-control delays and shipments that moved into Q3.
• Fiscal 2027 guidance calls for $250 million–$255 million in revenue and $66 million–$68 million in adjusted EBITDA, implying EBITDA growth of 5%–8% even as revenue grows 0%–2%. Management said the outlook includes Clinical Genomics’ revenue reset and restructuring-plan reinvestments, and was set conservatively.
• SDC grew 14.6% organically in Q2, largely reflecting a comparison with prior-year delivery delays, and its trailing 12-month revenue reached a record $103.9 million. However, a key product line responsible for much of the past-due backlog is only partially fixed, leaving a significant delivery-reliability issue unresolved.
• Mesa is restructuring Clinical Genomics to focus on pharmacogenomics, oncology, and high-utilization customer accounts; revenue is expected to be lower, but management expects profitability to improve and cited multiyear renewals from its three largest customers. The company expects about $9.3 million in annualized gross cost savings, reinvesting $4.3 million for a net reduction of about $5 million.
• Mesa repaid $20.1 million of debt in the first half and ended the quarter at 1.75x net leverage, within its target range. The board also authorized share repurchases of up to $40 million through December 2028, while management said debt reduction and investment in higher-return businesses remain priorities.

Mesa Laboratories Stock Down 0.3%

Shares of NASDAQ:MLAB traded down $0.43 during trading on Monday, hitting $127.82. 118,371 shares of the company were exchanged, compared to its average volume of 140,603. The stock has a market capitalization of $715.79 million, a P/E ratio of 152.17 and a beta of 1.08. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.79 and a quick ratio of 1.32. Mesa Laboratories has a 12-month low of $69.51 and a 12-month high of $144.35. The firm's 50 day moving average price is $128.30 and its 200-day moving average price is $104.95.

Mesa Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 30th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Monday, November 30th. Mesa Laboratories's payout ratio is currently 76.19%.

Insider Activity at Mesa Laboratories

In related news, Director John Sullivan sold 7,093 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $112.80, for a total value of $800,090.40. Following the transaction, the director directly owned 17,834 shares of the company's stock, valued at $2,011,675.20. This trade represents a 28.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director R Tripeny purchased 900 shares of the business's stock in a transaction that occurred on Thursday, August 13th. The shares were bought at an average price of $113.69 per share, for a total transaction of $102,321.00. Following the completion of the purchase, the director directly owned 6,298 shares in the company, valued at $716,019.62. This represents a 16.67% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 2.80% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MLAB. Weiss Ratings raised shares of Mesa Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. Wall Street Zen upgraded shares of Mesa Laboratories from a "buy" rating to a "strong-buy" rating in a report on Saturday, October 3rd. Finally, Wells Fargo & Company lifted their price target on shares of Mesa Laboratories from $94.00 to $110.00 and gave the company an "equal weight" rating in a research report on Friday, August 14th. Three equities research analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $110.00.

About Mesa Laboratories

Mesa Laboratories, Inc develops and manufactures products used for quality control, monitoring, and measurement in healthcare, pharmaceutical, industrial, and other regulated applications. The company's offerings are designed to help customers verify the performance of processes, equipment, and environmental conditions.

Mesa Laboratories' product portfolio includes sterilization assurance products, such as biological indicators and related monitoring systems, as well as instruments and consumables used in healthcare and laboratory settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.